title: Thermal Analysis Investigation of Dapoxetine and Vardenafil Hydrochlorides using Molecular Orbital Calculations.
abstract: OBJECTIVE
  Thermal analysis techniques have been used to study the thermal behavior of dapoxetine and vardenafil hydrochlorides and confirmed using semi-empirical molecular orbital calculations.
  
  
  METHODS
  Thermogravimetric analysis, derivative thermogravimetry, differential thermal analysis and differential scanning calorimetry were used to determine the thermal behavior and purity of the drugs under investigation. Thermodynamic parameters such as activation energy, enthalpy, entropy and Gibbs free energy were calculated.
  
  
  RESULTS
  Thermal behavior of DAP and VAR were confirmed using by semi-empirical molecular orbital calculations. The purity values were found to be 99.97% and 99.95% for dapoxetine and vardenafil hydrochlorides, respectively. The purity of dapoxetine and vardenafil hydrochlorides is similar to that found by reported methods according to DSC data.
  
  
  CONCLUSIONS
  Thermal analysis justifies its application in quality control of pharmaceutical compounds due to its simplicity, sensitivity and low operational costs.
authors.affiliation: National Organization for Drug Control and Research, P.O. Box 29, Cairo, Egypt.
authors.forename: Ali Kamal
authors.initials: AK
authors.lastname: Attia
authors.affiliation: Department of Chemistry, Faculty of Science, Ain Shams University, Egypt.
authors.forename: Eglal R
authors.initials: ER
authors.lastname: Souaya
authors.affiliation: National Organization for Drug Control and Research, P.O. Box 29, Cairo, Egypt.
authors.forename: Ethar A
authors.initials: EA
authors.lastname: Soliman
keywords: Dapoxetine hydrochloride; Differential scanning calorimetry; Molecular orbital calculations; Purity; Thermal analysis; Vardenafil hydrochloride
references.citation: Spectrochim Acta A Mol Biomol Spectrosc. 2005 Mar;61(5):799-805
references.pmid: 15683781
references.citation: Spectrochim Acta A Mol Biomol Spectrosc. 2006 May 15;64(2):363-71
references.pmid: 16386458
references.citation: Adv Pharm Bull. 2013;3(1):147-52
references.pmid: 24312828
references.citation: J Pharm Biomed Anal. 2009 Dec 5;50(5):724-8
references.pmid: 19574010
references.citation: Cryst Growth Des. 2008;8(1):14-16
references.pmid: 19367342
references.citation: J Pharm Biomed Anal. 2002 Jun 15;28(6):1011-40
references.pmid: 12049968
references.citation: Spectrochim Acta A Mol Biomol Spectrosc. 2015 Mar 5;138:49-57
references.pmid: 25437844
references.citation: Spectrochim Acta A Mol Biomol Spectrosc. 2007 Jun;67(2):522-30
references.pmid: 17030008
references.citation: Int J Androl. 2012 Aug;35(4):528-33
references.pmid: 22320846
references.citation: Ther Adv Urol. 2012 Oct;4(5):233-51
references.pmid: 23024705
references.citation: Adv Pharm Bull. 2013;3(2):419-24
references.pmid: 24312870